000105.KS
Yuhan Corporation [000105.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
000105.KS Stock Summary
Top 000105.KS Correlated Resources
000105.KS
Top 10 Correlated ETFs
000105.KS
Top 10 Correlated Stocks
000105.KS
000105.KS Financial details
000105.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 106.11K | 110.22K | 107.43K | 117.55K | 122.48K | |
| Net income per share | 7.91K | 4.17K | 2.9K | 13.99K | 7.44K | |
| Operating cash flow per share | 9.15K | 6.78K | 4.79K | 2.09K | 7.18K | |
| Free cash flow per share | 4.81K | 3.26K | 1.4K | -4.52K | 1.24K | |
| Cash per share | 36.4K | 34.48K | 30.11K | 32.34K | 31.7K | |
| Book value per share | 116.11K | 119.13K | 119.46K | 133.53K | 139.83K | |
| Tangible book value per share | 114.7K | 117.41K | 117.65K | 129.75K | 134.13K | |
| Share holders equity per share | 116.11K | 119.13K | 119.46K | 133.53K | 139.83K | |
| Interest debt per share | 10.05K | 8.87K | 6.86K | 9.13K | 9.27K | |
| Market cap | 519.52B | 569.13B | 566.37B | 875.05B | 760.67B | |
| Enterprise value | 396.73B | 446.41B | 383.63B | 644.65B | 631.85B | |
| P/E ratio | 4.76 | 9.9 | 14.16 | 4.54 | 7.42 | |
| Price to sales ratio | 0.36 | 0.37 | 0.38 | 0.54 | 0.45 | |
| POCF ratio | 4.12 | 6.09 | 8.58 | 30.35 | 7.68 | |
| PFCF ratio | 7.85 | 12.69 | 29.42 | -14.04 | 44.42 | |
| P/B Ratio | 0.32 | 0.35 | 0.34 | 0.48 | 0.39 | |
| PTB ratio | 0.32 | 0.35 | 0.34 | 0.48 | 0.39 | |
| EV to sales | 0.27 | 0.29 | 0.26 | 0.4 | 0.37 | |
| Enterprise value over EBITDA | 1.97 | 2.95 | 3.2 | 2.12 | 3.41 | |
| EV to operating cash flow | 3.15 | 4.78 | 5.81 | 22.36 | 6.38 | |
| EV to free cash flow | 5.99 | 9.95 | 19.93 | -10.34 | 36.89 | |
| Earnings yield | 0.21 | 0.1 | 0.07 | 0.22 | 0.13 | |
| Free cash flow yield | 0.13 | 0.08 | 0.03 | -0.07 | 0.02 | |
| Debt to equity | 0.07 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Debt to assets | 0.23 | 0.24 | 0.22 | 0.23 | 0.21 | |
| Net debt to EBITDA | -0.61 | -0.81 | -1.52 | -0.76 | -0.7 | |
| Current ratio | 3.87 | 3.18 | 3.17 | 3.13 | 2.83 | |
| Interest coverage | 19.22 | 13.66 | 4.04 | 31.07 | 16.51 | |
| Income quality | 1.16 | 1.63 | 1.65 | 0.15 | 0.97 | |
| Dividend Yield | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | |
| Payout ratio | 0.19 | 0.38 | 0.57 | 0.12 | 0.24 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.05 | 0.05 | 0.07 | 0.09 | 0.06 | |
| Intangibles to total assets | 0.01 | 0.02 | 0.01 | 0.02 | 0.04 | |
| Capex to operating cash flow | -0.48 | -0.52 | -0.71 | -3.16 | -0.83 | |
| Capex to revenue | -0.04 | -0.03 | -0.03 | -0.06 | -0.05 | |
| Capex to depreciation | -1.15 | -0.82 | -0.8 | -1.53 | -1.55 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 143.77K | 105.74K | 88.34K | 205K | 153.04K | |
| ROIC | 0.05 | 0.03 | 0.01 | 0.04 | 0.02 | |
| Return on tangible assets | 0.05 | 0.03 | 0.02 | 0.08 | 0.04 | |
| Graham Net | 10.8K | 5.62K | 2.99K | 1.78K | 3.36K | |
| Working capital | 793.2B | 761.25B | 764.72B | 813.34B | 792.12B | |
| Tangible asset value | 1580.59B | 1617.95B | 1621.26B | 1788B | 1848.3B | |
| Net current asset value | 581.16B | 588.88B | 649.74B | 648.5B | 696.17B | |
| Invested capital | 0.08 | 0.07 | 0.06 | 0.07 | 0.06 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 110.17B | 106.24B | 116.65B | 122.49B | 132.06B | |
| Average inventory | 261.58B | 250.42B | 219.45B | 251.99B | 263.38B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 34.42 | 29.72 | 38.53 | 42.12 | 44.44 | |
| Days of inventory on hand | 95.39 | 82.2 | 65 | 86.65 | 86.23 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 10.61 | 12.28 | 9.47 | 8.67 | 8.21 | |
| Inventory turnover | 3.83 | 4.44 | 5.62 | 4.21 | 4.23 | |
| ROE | 0.07 | 0.04 | 0.02 | 0.1 | 0.05 | |
| Capex per share | -4.35K | -3.53K | -3.39K | -6.62K | -5.94K |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 31.45K | 32.76K | 30.77K | 29.81K | 7.07K | |
| Net income per share | 2.48K | 2.23K | 1.24K | 1.16K | 499 | |
| Operating cash flow per share | -5.25K | -103.99 | 2.93K | 2.57K | 1.05K | |
| Free cash flow per share | -6.66K | -1.8K | 1.4K | 1.46K | 732.28 | |
| Cash per share | 32.12K | 31.41K | 31.7K | 0 | 6.88K | |
| Book value per share | 136.63K | 137.85K | 139.83K | 137.48K | 28.04K | |
| Tangible book value per share | 131.87K | 132.76K | 134.13K | 138.72K | 26.85K | |
| Share holders equity per share | 136.63K | 137.85K | 139.83K | 137.48K | 28.04K | |
| Interest debt per share | 9.37K | 8.59K | 9.1K | 134.58 | 1.59K | |
| Market cap | 836.46B | 800.64B | 814.42B | 792.37B | 3715.32B | |
| Enterprise value | 784.03B | 720.2B | 685.59B | 792.37B | 3628.65B | |
| P/E ratio | 6.12 | 6.52 | 11.89 | 12.43 | 27.25 | |
| Price to sales ratio | 1.93 | 1.77 | 1.92 | 1.93 | 7.69 | |
| POCF ratio | -11.57 | -558.72 | 20.2 | 22.37 | 51.79 | |
| PFCF ratio | -9.11 | -32.36 | 42.23 | 39.41 | 74.29 | |
| P/B Ratio | 0.44 | 0.42 | 0.42 | 0.42 | 1.94 | |
| PTB ratio | 0.44 | 0.42 | 0.42 | 0.42 | 1.94 | |
| EV to sales | 1.81 | 1.6 | 1.62 | 1.93 | 7.51 | |
| Enterprise value over EBITDA | 13.47 | 14.33 | 20.04 | 19.33 | 64.71 | |
| EV to operating cash flow | -10.84 | -502.59 | 17.01 | 22.37 | 50.59 | |
| EV to free cash flow | -8.54 | -29.11 | 35.55 | 39.41 | 72.56 | |
| Earnings yield | 0.04 | 0.04 | 0.02 | 0.02 | 0.01 | |
| Free cash flow yield | -0.11 | -0.03 | 0.02 | 0.03 | 0.01 | |
| Debt to equity | 0.03 | 0.02 | 0.02 | 0 | 0.01 | |
| Debt to assets | 0.23 | 0.22 | 0.21 | 0.23 | 0.21 | |
| Net debt to EBITDA | -0.9 | -1.6 | -3.76 | 0 | -1.55 | |
| Current ratio | 3.15 | 3.12 | 2.83 | 2.83 | 2.99 | |
| Interest coverage | 30.85 | 8.86 | 7.08 | 3.29 | 21.62 | |
| Income quality | -2.12 | -0.05 | 2.35 | 2.22 | 2.1 | |
| Dividend Yield | 0 | 0 | 0 | 0.03 | 0 | |
| Payout ratio | 0 | 0 | 0 | 1.64 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.02 | 0.27 | 0.01 | |
| Research and developement to revenue | 0.06 | 0.06 | 0.08 | 0 | 0.06 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.04 | 0 | 0.04 | |
| Capex to operating cash flow | 0.27 | 16.27 | -0.52 | -0.43 | -0.3 | |
| Capex to revenue | -0.04 | -0.05 | -0.05 | -0.04 | -0.04 | |
| Capex to depreciation | -1.48 | -1.87 | -1.67 | -1.4 | -2.03 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 87.29K | 83.12K | 62.53K | 59.81K | 17.74K | |
| ROIC | 0.01 | 0 | 0 | 0 | 0.01 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham Net | 863.02 | 1.1K | 3.36K | -41.33K | 1.27K | |
| Working capital | 828.65B | 820.16B | 792.12B | 874.81B | 876.57B | |
| Tangible asset value | 1817.26B | 1829.51B | 1848.3B | 0 | 1833.74B | |
| Net current asset value | 646.3B | 658.42B | 696.17B | 783.75B | 793.77B | |
| Invested capital | 0.07 | 0.06 | 0.06 | 0 | 0.06 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 167.51B | 170.08B | 159.51B | 0 | 177.4B | |
| Average inventory | 276.26B | 269.77B | 277.15B | 0 | 279.52B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 48.55 | 45.96 | 44.23 | 0 | 47.31 | |
| Days of inventory on hand | 84.09 | 73.43 | 85.81 | 0 | 74.54 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.85 | 1.96 | 2.03 | 0 | 1.9 | |
| Inventory turnover | 1.07 | 1.23 | 1.05 | 0 | 1.21 | |
| ROE | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Capex per share | -1.41K | -1.69K | -1.53K | -1.11K | -318.03 |
000105.KS Frequently Asked Questions
What is Yuhan Corporation stock symbol ?
Yuhan Corporation is a US stock and trading under the symbol 000105.KS
What is Yuhan Corporation stock quote today ?
Yuhan Corporation stock price is $57300 today.
Is Yuhan Corporation stock public?
Yes, Yuhan Corporation is a publicly traded company.
Company Profile
- Volume Average 539
- Market Capitalization 3840.38B
- Employee 1.85K
- Headquarters Seoul,US
- IPO Date 2005-09-29
-
Website
https://www.yuhan.co.kr 
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; and Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury. The company also provides ETC products, such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems, as well as anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. In addition, it offers over-the-counter (OTC) products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. Further, the company engages in dental business and provides implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and companion animals; and provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
